Die Wirkung der „bahnbrechenden“ Alzheimer-Medikamente ist „trivial“, kommt die Studie zu dem Schluss. Ausgewertete Daten aus 17 klinischen Studien mit Anti-Amyloid-Medikamenten ergaben keine „bedeutende Wirkung“ auf den kognitiven Rückgang.

https://www.theguardian.com/society/2026/apr/16/effect-gamechanger-alzheimers-drugs-trivial-review-concludes

Share.

4 Kommentare

  1. Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

    Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline

    Drugs that have been hailed as a gamechanger for the treatment of Alzheimer’s disease make no noticeable difference to patients, according to an extensive review.

    The analysis of clinical trials in people with mild cognitive impairment or mild dementia found that the effects of anti-amyloid drugs on cognition and dementia severity over 18 months were “trivial”, with improvements in functional ability “small at best”.

    The verdict is a blow to the new wave of drugs that are designed to slow Alzheimer’s by clearing clumps of amyloid protein that build up in the brain. Amyloid plaques are a hallmark of Alzheimer’s disease, along with another protein called tau which forms toxic tangles in neurons.

    The Cochrane review drew on gold standard methods to assess data from published clinical trials, but was criticised by some researchers and charities for combining results from older, failed drugs with those from newer, more effective medicines.

    For those interested, here’s the link to the peer reviewed journal article:

    https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016297/full

  2. agnostic_science on

    We had already knowm that there had been massive fraud in amyloid research. Seeing outcomes like this makes me wonder if there was ever anything of value in that field at all. 

    Gamechanging drugs only to the people pushing the drugs and bad science apparently.

  3. […] The Cochrane review drew on gold standard methods to assess data from published clinical trials, **but was criticised by some researchers and charities for combining results from older, failed drugs with those from newer, more effective medicines.**

    “It’s not surprising that if you pool results from effective and ineffective treatments you end up with a small or absent average treatment effect,” said Charles Marshall, professor of clinical neurology at Queen Mary, University of London.

Leave A Reply